Report cover image

Global Radiopharmaceutical (Oral Route) Market Analysis and Forecast 2025-2031

Publisher APO Research, Inc.
Published Aug 16, 2025
Length 192 Pages
SKU # APRC20361814

Description

Summary

According to APO Research, The global Radiopharmaceutical (Oral Route) market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Radiopharmaceutical (Oral Route) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Radiopharmaceutical (Oral Route) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Radiopharmaceutical (Oral Route) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Radiopharmaceutical (Oral Route) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Radiopharmaceutical (Oral Route) include Eli Lilly, Bayer, Triad Isotopes, SIEMENS, Nordion, Navidea, Mallinckrodt, Lantheus and Jubilant Pharma, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Radiopharmaceutical (Oral Route), sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Radiopharmaceutical (Oral Route), also provides the sales of main regions and countries. Of the upcoming market potential for Radiopharmaceutical (Oral Route), and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Radiopharmaceutical (Oral Route) sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Radiopharmaceutical (Oral Route) market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Radiopharmaceutical (Oral Route) sales, projected growth trends, production technology, application and end-user industry.

Radiopharmaceutical (Oral Route) Segment by Company

Eli Lilly
Bayer
Triad Isotopes
SIEMENS
Nordion
Navidea
Mallinckrodt
Lantheus
Jubilant Pharma
IBA Group
GE Healthcare
Dongcheng
China Isotope & Radiation
Bracco Imaging
Advanced Accelerator Applications
Radiopharmaceutical (Oral Route) Segment by Type

Actinium-225
Holmium-166
Radium-223
Lutetium-177
Other
Radiopharmaceutical (Oral Route) Segment by Application

Oncology
Cardiology
Other
Radiopharmaceutical (Oral Route) Segment by Region

North America
United States
Canada
Europe
v
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Radiopharmaceutical (Oral Route) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Radiopharmaceutical (Oral Route) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Radiopharmaceutical (Oral Route).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Sales (consumption), revenue of Radiopharmaceutical (Oral Route) in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 4: Detailed analysis of Radiopharmaceutical (Oral Route) manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Radiopharmaceutical (Oral Route) sales, revenue, price, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.
Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.
Chapter 10: China type, by application, sales, and revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.
Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 14: The main concluding insights of the report.

Table of Contents

192 Pages
1 Market Overview
1.1 Product Definition
1.2 Radiopharmaceutical (Oral Route) Market by Type
1.2.1 Global Radiopharmaceutical (Oral Route) Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Actinium-225
1.2.3 Holmium-166
1.2.4 Radium-223
1.2.5 Lutetium-177
1.2.6 Other
1.3 Radiopharmaceutical (Oral Route) Market by Application
1.3.1 Global Radiopharmaceutical (Oral Route) Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Oncology
1.3.3 Cardiology
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 Radiopharmaceutical (Oral Route) Market Dynamics
2.1 Radiopharmaceutical (Oral Route) Industry Trends
2.2 Radiopharmaceutical (Oral Route) Industry Drivers
2.3 Radiopharmaceutical (Oral Route) Industry Opportunities and Challenges
2.4 Radiopharmaceutical (Oral Route) Industry Restraints
3 Global Market Growth Prospects
3.1 Global Radiopharmaceutical (Oral Route) Revenue Estimates and Forecasts (2020-2031)
3.2 Global Radiopharmaceutical (Oral Route) Revenue by Region
3.2.1 Global Radiopharmaceutical (Oral Route) Revenue by Region: 2020 VS 2024 VS 2031
3.2.2 Global Radiopharmaceutical (Oral Route) Revenue by Region (2020-2025)
3.2.3 Global Radiopharmaceutical (Oral Route) Revenue by Region (2026-2031)
3.2.4 Global Radiopharmaceutical (Oral Route) Revenue Market Share by Region (2020-2031)
3.3 Global Radiopharmaceutical (Oral Route) Sales Estimates and Forecasts 2020-2031
3.4 Global Radiopharmaceutical (Oral Route) Sales by Region
3.4.1 Global Radiopharmaceutical (Oral Route) Sales by Region: 2020 VS 2024 VS 2031
3.4.2 Global Radiopharmaceutical (Oral Route) Sales by Region (2020-2025)
3.4.3 Global Radiopharmaceutical (Oral Route) Sales by Region (2026-2031)
3.4.4 Global Radiopharmaceutical (Oral Route) Sales Market Share by Region (2020-2031)
3.5 US & Canada & Mexico
3.6 Europe
3.7 China
3.8 Asia (Excluding China)
3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
4.1 Global Radiopharmaceutical (Oral Route) Revenue by Manufacturers
4.1.1 Global Radiopharmaceutical (Oral Route) Revenue by Manufacturers (2020-2025)
4.1.2 Global Radiopharmaceutical (Oral Route) Revenue Market Share by Manufacturers (2020-2025)
4.1.3 Global Radiopharmaceutical (Oral Route) Manufacturers Revenue Share Top 10 and Top 5 in 2024
4.2 Global Radiopharmaceutical (Oral Route) Sales by Manufacturers
4.2.1 Global Radiopharmaceutical (Oral Route) Sales by Manufacturers (2020-2025)
4.2.2 Global Radiopharmaceutical (Oral Route) Sales Market Share by Manufacturers (2020-2025)
4.2.3 Global Radiopharmaceutical (Oral Route) Manufacturers Sales Share Top 10 and Top 5 in 2024
4.3 Global Radiopharmaceutical (Oral Route) Sales Price by Manufacturers (2020-2025)
4.4 Global Radiopharmaceutical (Oral Route) Key Manufacturers Ranking, 2023 VS 2024 VS 2025
4.5 Global Radiopharmaceutical (Oral Route) Key Manufacturers Manufacturing Sites & Headquarters
4.6 Global Radiopharmaceutical (Oral Route) Manufacturers, Product Type & Application
4.7 Global Radiopharmaceutical (Oral Route) Manufacturers' Establishment Date
4.8 Market Competitive Analysis
4.8.1 Global Radiopharmaceutical (Oral Route) Market CR5 and HHI
4.8.2 2024 Radiopharmaceutical (Oral Route) Tier 1, Tier 2, and Tier 3
5 Radiopharmaceutical (Oral Route) Market by Type
5.1 Global Radiopharmaceutical (Oral Route) Revenue by Type
5.1.1 Global Radiopharmaceutical (Oral Route) Revenue by Type (2020 VS 2024 VS 2031)
5.1.2 Global Radiopharmaceutical (Oral Route) Revenue by Type (2020-2031) & (US$ Million)
5.1.3 Global Radiopharmaceutical (Oral Route) Revenue Market Share by Type (2020-2031)
5.2 Global Radiopharmaceutical (Oral Route) Sales by Type
5.2.1 Global Radiopharmaceutical (Oral Route) Sales by Type (2020 VS 2024 VS 2031)
5.2.2 Global Radiopharmaceutical (Oral Route) Sales by Type (2020-2031) & (K Units)
5.2.3 Global Radiopharmaceutical (Oral Route) Sales Market Share by Type (2020-2031)
5.3 Global Radiopharmaceutical (Oral Route) Price by Type
6 Radiopharmaceutical (Oral Route) Market by Application
6.1 Global Radiopharmaceutical (Oral Route) Revenue by Application
6.1.1 Global Radiopharmaceutical (Oral Route) Revenue by Application (2020 VS 2024 VS 2031)
6.1.2 Global Radiopharmaceutical (Oral Route) Revenue by Application (2020-2031) & (US$ Million)
6.1.3 Global Radiopharmaceutical (Oral Route) Revenue Market Share by Application (2020-2031)
6.2 Global Radiopharmaceutical (Oral Route) Sales by Application
6.2.1 Global Radiopharmaceutical (Oral Route) Sales by Application (2020 VS 2024 VS 2031)
6.2.2 Global Radiopharmaceutical (Oral Route) Sales by Application (2020-2031) & (K Units)
6.2.3 Global Radiopharmaceutical (Oral Route) Sales Market Share by Application (2020-2031)
6.3 Global Radiopharmaceutical (Oral Route) Price by Application
7 Company Profiles
7.1 Eli Lilly
7.1.1 Eli Lilly Comapny Information
7.1.2 Eli Lilly Business Overview
7.1.3 Eli Lilly Radiopharmaceutical (Oral Route) Sales, Revenue, Price and Gross Margin (2020-2025)
7.1.4 Eli Lilly Radiopharmaceutical (Oral Route) Product Portfolio
7.1.5 Eli Lilly Recent Developments
7.2 Bayer
7.2.1 Bayer Comapny Information
7.2.2 Bayer Business Overview
7.2.3 Bayer Radiopharmaceutical (Oral Route) Sales, Revenue, Price and Gross Margin (2020-2025)
7.2.4 Bayer Radiopharmaceutical (Oral Route) Product Portfolio
7.2.5 Bayer Recent Developments
7.3 Triad Isotopes
7.3.1 Triad Isotopes Comapny Information
7.3.2 Triad Isotopes Business Overview
7.3.3 Triad Isotopes Radiopharmaceutical (Oral Route) Sales, Revenue, Price and Gross Margin (2020-2025)
7.3.4 Triad Isotopes Radiopharmaceutical (Oral Route) Product Portfolio
7.3.5 Triad Isotopes Recent Developments
7.4 SIEMENS
7.4.1 SIEMENS Comapny Information
7.4.2 SIEMENS Business Overview
7.4.3 SIEMENS Radiopharmaceutical (Oral Route) Sales, Revenue, Price and Gross Margin (2020-2025)
7.4.4 SIEMENS Radiopharmaceutical (Oral Route) Product Portfolio
7.4.5 SIEMENS Recent Developments
7.5 Nordion
7.5.1 Nordion Comapny Information
7.5.2 Nordion Business Overview
7.5.3 Nordion Radiopharmaceutical (Oral Route) Sales, Revenue, Price and Gross Margin (2020-2025)
7.5.4 Nordion Radiopharmaceutical (Oral Route) Product Portfolio
7.5.5 Nordion Recent Developments
7.6 Navidea
7.6.1 Navidea Comapny Information
7.6.2 Navidea Business Overview
7.6.3 Navidea Radiopharmaceutical (Oral Route) Sales, Revenue, Price and Gross Margin (2020-2025)
7.6.4 Navidea Radiopharmaceutical (Oral Route) Product Portfolio
7.6.5 Navidea Recent Developments
7.7 Mallinckrodt
7.7.1 Mallinckrodt Comapny Information
7.7.2 Mallinckrodt Business Overview
7.7.3 Mallinckrodt Radiopharmaceutical (Oral Route) Sales, Revenue, Price and Gross Margin (2020-2025)
7.7.4 Mallinckrodt Radiopharmaceutical (Oral Route) Product Portfolio
7.7.5 Mallinckrodt Recent Developments
7.8 Lantheus
7.8.1 Lantheus Comapny Information
7.8.2 Lantheus Business Overview
7.8.3 Lantheus Radiopharmaceutical (Oral Route) Sales, Revenue, Price and Gross Margin (2020-2025)
7.8.4 Lantheus Radiopharmaceutical (Oral Route) Product Portfolio
7.8.5 Lantheus Recent Developments
7.9 Jubilant Pharma
7.9.1 Jubilant Pharma Comapny Information
7.9.2 Jubilant Pharma Business Overview
7.9.3 Jubilant Pharma Radiopharmaceutical (Oral Route) Sales, Revenue, Price and Gross Margin (2020-2025)
7.9.4 Jubilant Pharma Radiopharmaceutical (Oral Route) Product Portfolio
7.9.5 Jubilant Pharma Recent Developments
7.10 IBA Group
7.10.1 IBA Group Comapny Information
7.10.2 IBA Group Business Overview
7.10.3 IBA Group Radiopharmaceutical (Oral Route) Sales, Revenue, Price and Gross Margin (2020-2025)
7.10.4 IBA Group Radiopharmaceutical (Oral Route) Product Portfolio
7.10.5 IBA Group Recent Developments
7.11 GE Healthcare
7.11.1 GE Healthcare Comapny Information
7.11.2 GE Healthcare Business Overview
7.11.3 GE Healthcare Radiopharmaceutical (Oral Route) Sales, Revenue, Price and Gross Margin (2020-2025)
7.11.4 GE Healthcare Radiopharmaceutical (Oral Route) Product Portfolio
7.11.5 GE Healthcare Recent Developments
7.12 Dongcheng
7.12.1 Dongcheng Comapny Information
7.12.2 Dongcheng Business Overview
7.12.3 Dongcheng Radiopharmaceutical (Oral Route) Sales, Revenue, Price and Gross Margin (2020-2025)
7.12.4 Dongcheng Radiopharmaceutical (Oral Route) Product Portfolio
7.12.5 Dongcheng Recent Developments
7.13 China Isotope & Radiation
7.13.1 China Isotope & Radiation Comapny Information
7.13.2 China Isotope & Radiation Business Overview
7.13.3 China Isotope & Radiation Radiopharmaceutical (Oral Route) Sales, Revenue, Price and Gross Margin (2020-2025)
7.13.4 China Isotope & Radiation Radiopharmaceutical (Oral Route) Product Portfolio
7.13.5 China Isotope & Radiation Recent Developments
7.14 Bracco Imaging
7.14.1 Bracco Imaging Comapny Information
7.14.2 Bracco Imaging Business Overview
7.14.3 Bracco Imaging Radiopharmaceutical (Oral Route) Sales, Revenue, Price and Gross Margin (2020-2025)
7.14.4 Bracco Imaging Radiopharmaceutical (Oral Route) Product Portfolio
7.14.5 Bracco Imaging Recent Developments
7.15 Advanced Accelerator Applications
7.15.1 Advanced Accelerator Applications Comapny Information
7.15.2 Advanced Accelerator Applications Business Overview
7.15.3 Advanced Accelerator Applications Radiopharmaceutical (Oral Route) Sales, Revenue, Price and Gross Margin (2020-2025)
7.15.4 Advanced Accelerator Applications Radiopharmaceutical (Oral Route) Product Portfolio
7.15.5 Advanced Accelerator Applications Recent Developments
8 North America
8.1 North America Radiopharmaceutical (Oral Route) Market Size by Type
8.1.1 North America Radiopharmaceutical (Oral Route) Revenue by Type (2020-2031)
8.1.2 North America Radiopharmaceutical (Oral Route) Sales by Type (2020-2031)
8.1.3 North America Radiopharmaceutical (Oral Route) Price by Type (2020-2031)
8.2 North America Radiopharmaceutical (Oral Route) Market Size by Application
8.2.1 North America Radiopharmaceutical (Oral Route) Revenue by Application (2020-2031)
8.2.2 North America Radiopharmaceutical (Oral Route) Sales by Application (2020-2031)
8.2.3 North America Radiopharmaceutical (Oral Route) Price by Application (2020-2031)
8.3 North America Radiopharmaceutical (Oral Route) Market Size by Country
8.3.1 North America Radiopharmaceutical (Oral Route) Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
8.3.2 North America Radiopharmaceutical (Oral Route) Sales by Country (2020 VS 2024 VS 2031)
8.3.3 North America Radiopharmaceutical (Oral Route) Price by Country (2020-2031)
8.3.4 United States
8.3.5 Canada
9 Europe
9.1 Europe Radiopharmaceutical (Oral Route) Market Size by Type
9.1.1 Europe Radiopharmaceutical (Oral Route) Revenue by Type (2020-2031)
9.1.2 Europe Radiopharmaceutical (Oral Route) Sales by Type (2020-2031)
9.1.3 Europe Radiopharmaceutical (Oral Route) Price by Type (2020-2031)
9.2 Europe Radiopharmaceutical (Oral Route) Market Size by Application
9.2.1 Europe Radiopharmaceutical (Oral Route) Revenue by Application (2020-2031)
9.2.2 Europe Radiopharmaceutical (Oral Route) Sales by Application (2020-2031)
9.2.3 Europe Radiopharmaceutical (Oral Route) Price by Application (2020-2031)
9.3 Europe Radiopharmaceutical (Oral Route) Market Size by Country
9.3.1 Europe Radiopharmaceutical (Oral Route) Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
9.3.2 Europe Radiopharmaceutical (Oral Route) Sales by Country (2020 VS 2024 VS 2031)
9.3.3 Europe Radiopharmaceutical (Oral Route) Price by Country (2020-2031)
9.3.4 v
9.3.5 France
9.3.6 U.K.
9.3.7 Italy
9.3.8 Netherlands
10 China
10.1 China Radiopharmaceutical (Oral Route) Market Size by Type
10.1.1 China Radiopharmaceutical (Oral Route) Revenue by Type (2020-2031)
10.1.2 China Radiopharmaceutical (Oral Route) Sales by Type (2020-2031)
10.1.3 China Radiopharmaceutical (Oral Route) Price by Type (2020-2031)
10.2 China Radiopharmaceutical (Oral Route) Market Size by Application
10.2.1 China Radiopharmaceutical (Oral Route) Revenue by Application (2020-2031)
10.2.2 China Radiopharmaceutical (Oral Route) Sales by Application (2020-2031)
10.2.3 China Radiopharmaceutical (Oral Route) Price by Application (2020-2031)
11 Asia (Excluding China)
11.1 Asia Radiopharmaceutical (Oral Route) Market Size by Type
11.1.1 Asia Radiopharmaceutical (Oral Route) Revenue by Type (2020-2031)
11.1.2 Asia Radiopharmaceutical (Oral Route) Sales by Type (2020-2031)
11.1.3 Asia Radiopharmaceutical (Oral Route) Price by Type (2020-2031)
11.2 Asia Radiopharmaceutical (Oral Route) Market Size by Application
11.2.1 Asia Radiopharmaceutical (Oral Route) Revenue by Application (2020-2031)
11.2.2 Asia Radiopharmaceutical (Oral Route) Sales by Application (2020-2031)
11.2.3 Asia Radiopharmaceutical (Oral Route) Price by Application (2020-2031)
11.3 Asia Radiopharmaceutical (Oral Route) Market Size by Country
11.3.1 Asia Radiopharmaceutical (Oral Route) Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
11.3.2 Asia Radiopharmaceutical (Oral Route) Sales by Country (2020 VS 2024 VS 2031)
11.3.3 Asia Radiopharmaceutical (Oral Route) Price by Country (2020-2031)
11.3.4 Japan
11.3.5 South Korea
11.3.6 India
11.3.7 Australia
11.3.8 Taiwan
11.3.9 Southeast Asia
12 South America, Middle East and Africa
12.1 SAMEA Radiopharmaceutical (Oral Route) Market Size by Type
12.1.1 SAMEA Radiopharmaceutical (Oral Route) Revenue by Type (2020-2031)
12.1.2 SAMEA Radiopharmaceutical (Oral Route) Sales by Type (2020-2031)
12.1.3 SAMEA Radiopharmaceutical (Oral Route) Price by Type (2020-2031)
12.2 SAMEA Radiopharmaceutical (Oral Route) Market Size by Application
12.2.1 SAMEA Radiopharmaceutical (Oral Route) Revenue by Application (2020-2031)
12.2.2 SAMEA Radiopharmaceutical (Oral Route) Sales by Application (2020-2031)
12.2.3 SAMEA Radiopharmaceutical (Oral Route) Price by Application (2020-2031)
12.3 SAMEA Radiopharmaceutical (Oral Route) Market Size by Country
12.3.1 SAMEA Radiopharmaceutical (Oral Route) Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
12.3.2 SAMEA Radiopharmaceutical (Oral Route) Sales by Country (2020 VS 2024 VS 2031)
12.3.3 SAMEA Radiopharmaceutical (Oral Route) Price by Country (2020-2031)
12.3.4 Brazil
12.3.5 Argentina
12.3.6 Chile
12.3.7 Colombia
12.3.8 Peru
12.3.9 Saudi Arabia
12.3.10 Israel
12.3.11 UAE
12.3.12 Turkey
12.3.13 Iran
12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
13.1 Radiopharmaceutical (Oral Route) Value Chain Analysis
13.1.1 Radiopharmaceutical (Oral Route) Key Raw Materials
13.1.2 Raw Materials Key Suppliers
13.1.3 Manufacturing Cost Structure
13.1.4 Radiopharmaceutical (Oral Route) Production Mode & Process
13.2 Radiopharmaceutical (Oral Route) Sales Channels Analysis
13.2.1 Direct Comparison with Distribution Share
13.2.2 Radiopharmaceutical (Oral Route) Distributors
13.2.3 Radiopharmaceutical (Oral Route) Customers
14 Concluding Insights
15 Appendix
15.1 Reasons for Doing This Study
15.2 Research Methodology
15.3 Research Process
15.4 Authors List of This Report
15.5 Data Source
15.5.1 Secondary Sources
15.5.2 Primary Sources
15.6 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.